A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Registration Number
- JPRN-jRCT2080223944
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 360
Participants must have gradual and progressive change in memory function for >6 months.
- Participants must have a family member or close friend who is with you at least 10 hours per week and can attend study appointments.
- Participants must not have significant neurological disease affecting the nervous system, other than AD, that affects cognition or may affect completion of the study.
- Participants must not have serious or unstable illness that could interfere with the analysis of the study or has a life expectancy <24 months.
- Participants must not have history of cancer within the last 5 years with the exception of certain types of skin, cervical, prostate, and other cancers that are not likely to recur or spread.
- Participants must not have serious risk for suicide.
- Participants must not have history of drug or alcohol use disorder within the last 2 years.
- Participants must not have multiple severe drug allergies
- Participants must not have HIV, Hepatitis B or Hepatitis C
- Participants must not be receiving gamma globulin (IgG) or intravenous immunoglobulin (IVIG) therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method efficacy<br>Change from baseline on the iADRS.
- Secondary Outcome Measures
Name Time Method